[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334032-105":59,"doc-detail-334032-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nsg2-a-promising-prognostic-marker-shaping-the-immune-landscape-of-breast-cancer","NSG2 - a promising prognostic marker shaping the immune landscape of breast cancer","","Breast cancer remains a major global cause of mortality, and improved biomarker understanding is needed to enhance diagnosis and long-term therapeutic outcomes. This study retrospectively evaluated tumor and normal samples from 228 breast cancer cases and 51 controls, integrating bioinformatics with multiplex immunohistochemistry to assess NSG2 expression. NSG2 was detected in cancer and adjacent stromal cells, with higher expression in cancer cells linked to larger tumors, distant metastasis, and advanced clinical stage, and NSG2 identified as an independent prognostic factor. Elevated NSG2 in cancer and stroma correlated with increased tumor-infiltrating CD4+ T, CD8+ T, and Lamp3+ dendritic cells, while stroma NSG2 showed negative association with CD20+ B cells and related to CTLA-4 levels.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nsg2-a-promising-prognostic-marker-shaping-the-immune-landscape-of-breast-cancer/334032/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nsg2-a-promising-prognostic-marker-shaping-the-immune-landscape-of-breast-cancer/334032.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does NSG2 play in breast cancer immune microenvironment?","Question",{"text":112,"@type":113},"NSG2 is present in both breast cancer cells and adjacent stromal cells and is described as a significant component of the breast cancer immune microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was NSG2 expression assessed in this study?",{"text":117,"@type":113},"NSG2 expression was evaluated through bioinformatics and multiplex immunohistochemistry using tumor samples from breast cancer cases and normal samples.",{"name":119,"@type":110,"acceptedAnswer":120},"Is NSG2 a useful prognostic marker, and with which immune features is it associated?",{"text":121,"@type":113},"NSG2 expression in both cancer and stromal cells was identified as an independent prognostic factor. Higher NSG2 levels correlated with increased CD4+ T, CD8+ T, and Lamp3+ dendritic cell infiltration, negative correlation with CD20+ B cells in stroma, and association with CTLA-4 levels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334032,1790918376,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Original Research PUBLISHED 18 October 2024  \nDOI 10.3389/fimmu.2024.1487447  \nOPEN ACCESS  \nEDITED BY  \nMinghua Ren,  \nFirst Afﬁliated Hospital of Harbin Medical University, China  \nREVIEWED BY  \nZhijie Xu,  \nCentral South University, China Peng Luo,  \nThe University of Hong Kong, Hong Kong SAR, China  \n*CORRESPONDENCE  \nQichao Ni  \n [nqcuser@163.com](nqcuser@163.com)  \nRECEIVED 28 August 2024  \nACCEPTED 30 September 2024  \nPUBLISHED 18 October 2024  \nCITATION  \nLi X, Gu Q, Sun P, Yang L, Zhang X, Lu Band Ni Q (2024) NSG2: a promising prognostic marker shaping the immune landscape of breast cancer.  \nFront. Immunol. 15:1487447 .  \ndoi: 10.3389/fimmu.2024.1487447  \nCOPYRIGHT  \n© 2024 Li, Gu, Sun, Yang, Zhang, Lu and Ni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nNSG2: a promising prognostic marker shaping the immune landscape of breast cancer  \nXuan Li 1, Qiming Gu 1, Pingping Sun 2, Lei Yang 2, Xiaojing Zhang 2, Bing Lu 2 and Qichao Ni 1*  \n1 Department of General Surgery, Afﬁliated Hospital of Nantong University & Medical School of Nantong University, Nantong, China, 2Clinical and Translational Research Center, Afﬁliated Hospital of Nantong University & Department of Oncology, Medical School of Nantong University, Nantong, Jiangsu, China  \nBackground: Breast cancer (BC) remains a signiﬁcant health issue globally and most common cause of mortality in women. Enhancing our understanding on biomarkers may greatly improve both diagnostic and therapeutic approaches to this disease.  \nMethods: We retrospectively assessed tumor samples from 228 BC cases and 51 normal samples, alongside relevant clinical data. Neuronal vesicle trafﬁcking associated 2(NSG2) expression was evaluated through bioinformatics and multiplex immunohistochemistry. Associations between NSG2 expression, tumor-inﬁltrating immune cells (TIICs), immune checkpoints, and clinical outcomes were investigated.  \nResults: NSG2 was present in both breast cancer cells and adjacent stromal cells. Increased NSG2 expression in cancer cells correlated with greater tumor size, distant metastasis, and more advanced clinical stages. Kaplan-Meier survival and multivariate analyses identiﬁed NSG2 expression in both cancer and stromal cells as an independent prognostic factor for breast cancer survival. Elevated NSG2 levels both in cancer and stroma cells were linked to increased CD4+ T, CD8+ T, and Lamp3+ dendritic cells inﬁltration in stromal regions (P \u003C 0 . 05) . Conversely, the expression of NSG2 in the stroma was negatively correlated with CD20+ B cells (P \u003C 0 . 05) . Additionally, NSG2 expression was found to be associated with CTLA-4 levels (P \u003C 0 . 05) .  \nConclusion: NSG2 seems to be a signiﬁcant component of the BC immune microenvironment and may serve as an important prognostic marker.  \nKEYWORDS  \nNSG2, breast cancer, tumor microenvironment, prognosis, biomarker  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nBreast cancer (BC) is the most common cancer and a leading cause of cancer-related deaths in women worldwide (1, 2), with treatment decisions often based on molecular proﬁling of BC (3, 4) . BCclassiﬁcation has traditionally been based on its receptors, and Her-2 expression to guide treatment choices (5). However, issues like drug resistance continue to pose signiﬁcant challenges, underscoring the need for new strategies to enhance long-term patient outcomes (6).  \nImmune cells were traditionally considered inhibitors of cancer progression (7) . However, emerging evidence reveals a more complex role for the immune microenvi","cbCaio21MCwpvJ3J","https://ap.wps.com/l/cbCaio21MCwpvJ3J","pdf",18026671,"English","# 1 Introduction\n## Cancer and immune microenvironment background\n## Neural elements and neuronal vesicle trafficking\n# Methods\n## Patient cohorts and sample assessment\n## NSG2 evaluation using bioinformatics and multiplex immunohistochemistry\n## Immune infiltration, checkpoints, and outcomes analysis\n# Results\n## NSG2 localization in cancer and stromal cells\n## Clinical correlations and prognostic value\n## Associations with immune cell infiltration and CTLA-4","[{\"question\":\"What role does NSG2 play in breast cancer immune microenvironment?\",\"answer\":\"NSG2 is present in both breast cancer cells and adjacent stromal cells and is described as a significant component of the breast cancer immune microenvironment.\"},{\"question\":\"How was NSG2 expression assessed in this study?\",\"answer\":\"NSG2 expression was evaluated through bioinformatics and multiplex immunohistochemistry using tumor samples from breast cancer cases and normal samples.\"},{\"question\":\"Is NSG2 a useful prognostic marker, and with which immune features is it associated?\",\"answer\":\"NSG2 expression in both cancer and stromal cells was identified as an independent prognostic factor. Higher NSG2 levels correlated with increased CD4+ T, CD8+ T, and Lamp3+ dendritic cell infiltration, negative correlation with CD20+ B cells in stroma, and association with CTLA-4 levels.\"}]","NSG2 - a promising prognostic marker shaping the immune landscape of breast cancer | PDF",1790005079,23]